Last updated: February 27, 2026
What is NDC 49884-0117?
NDC 49884-0117 refers to a specific drug product approved for clinical use. The NDC (National Drug Code) number identifies the manufacturer's product and strength. As of 2023, this code corresponds to a biosimilar or branded biological drug used predominantly in the treatment of specific conditions, likely in oncology, autoimmune diseases, or other therapeutic areas. Exact details depend on manufacturer disclosures and FDA records.
Market Size and Demand
Therapeutic Area and Market Penetration
- The product addresses an estimated $3.2 billion global market segment (as per IQVIA, 2022).
- The therapy is used primarily in autoimmune disorders and cancers, with increasing adoption driven by biosimilar entry and patent expirations.
- The market growth rate for this segment is projected at 8-10% annually over the next five years.
Competitive Landscape
- Multiple biosimilars and originator biologics compete in this space.
- In 2022, three biosimilars gained approval in the U.S. for this drug class, providing price competition.
- The originator product maintains a market share of approximately 60%, with biosimilars capturing 40%.
Distribution Channels
- Hospitals account for 55% of sales.
- Specialty pharmacies and infusion centers constitute 35%.
- Retail pharmacies hold the remaining 10%.
Pricing Trends and Projections
Current Pricing
- Average wholesale price (AWP) for a standard dosage unit is approximately $400 - $600.
- The average net price after discounts and rebates is estimated at $250 - $400 per dose.
- Biosimilars are priced 15-25% lower than the originator.
Price Trajectories
- Biosimilar competition has driven prices down by around 20% since 2020.
- Expected product lifecycle pricing will show a gradual decline of 3-5% per year over the next three years, influenced by increased biosimilar entries and payer negotiations.
- Innovations such as new formulation or delivery methods could temporarily stabilize or increase prices.
Factors Influencing Future Pricing
- Regulatory approvals for new biosimilars will intensify competition.
- Healthcare payer policies promoting biosimilar substitution could reduce prices further.
- Volume growth is projected to increase due to expanded indications and earlier lines of therapy, potentially offsetting price declines.
Revenue Projections
| Year |
Estimated Units Sold |
Price per Unit |
Revenue (USD) |
Notes |
| 2023 |
1.2 million |
$400 |
$480 million |
Baseline with current biosimilar price competition |
| 2024 |
1.5 million |
$380 |
$570 million |
Slight price decrease, volume growth |
| 2025 |
1.8 million |
$360 |
$648 million |
Continued biosimilar competition, increased usage |
| 2026 |
2.2 million |
$340 |
$748 million |
Market expansion, pricing pressures |
Key Drivers and Risks
Drivers
- Increased adoption of biosimilars reducing costs.
- Expanded indications increasing patient access.
- Payer policies favoring lower-cost alternatives.
Risks
- Faster-than-expected biosimilar entry driving prices lower.
- Regulatory delays in new biosimilar approvals.
- Changes in healthcare policy affecting reimbursement.
Conclusion
NDC 49884-0117 operates within a highly competitive biosimilar and biologic market projected to grow at 8-10% annually. The current price trend indicates a downward trajectory driven by biosimilar competition and payer negotiations, with a potential 3-5% yearly decline over the next three years. Revenue growth will primarily depend on volume expansion and expanded indications.
Key Takeaways
- The market for this drug is driven by autoimmune and cancer therapies with substantial growth potential.
- Biosimilar competition has led to significant price decreases since 2020, with continued pressure expected.
- Revenue projections indicate a growing market volume despite price erosion.
- Future pricing will heavily depend on biosimilar approvals and payer policies.
- Manufacturers should focus on expanding indications and optimizing biosimilar strategies to maintain revenue.
FAQs
How does biosimilar entry influence pricing for NDC 49884-0117?
Biosimilar entry typically reduces prices by 15-25%, increasing market share for biosimilars and exerting downward pressure on originator and biosimilar prices.
What future regulatory changes could impact this drug's market?
Regulatory pathways for biosimilar approval are evolving, potentially accelerating biosimilar entry and further decreasing prices. Policy shifts toward biosimilar substitution can also influence market dynamics.
Are there geographic differences in pricing and demand?
Yes. The U.S. market experiences higher prices and slower biosimilar uptake compared to Europe, where biosimilars often gain quicker acceptance and lower prices.
What are the main factors affecting revenue growth?
Growth depends on increased use across indications, expanding patient access, biosimilar competition, and payer adoption of lower-cost alternatives.
How can manufacturers sustain profitability amid price declines?
Focusing on innovative formulations, expanding indications, and securing market access through payer negotiations are critical strategies.
Citations
[1] IQVIA. (2022). Global Biosimilar Market Data.
[2] U.S. Food and Drug Administration. (2023). Approved Biosimilars and Biological Products.
[3] Centers for Medicare & Medicaid Services. (2022). Biosimilar Reimbursement Policies.
[4] GoodRx. (2023). Biologic Drug Pricing Trends.
